131 related articles for article (PubMed ID: 38282338)
41. Active surrender.
Collisson EA
Pigment Cell Melanoma Res; 2012 May; 25(3):292-3. PubMed ID: 22629566
[No Abstract] [Full Text] [Related]
42. A Case of Giant Primary Dermal Melanoma with BRAF V600E Mutation.
Imamura T; Nakamura Y; Teramoto Y; Sato S; Asami Y; Arai E; Yamamoto A
Acta Derm Venereol; 2016 Aug; 96(6):840-1. PubMed ID: 26984828
[No Abstract] [Full Text] [Related]
43. Activation of the Mitochondrial Fragmentation Protein DRP1 Correlates with BRAF(V600E) Melanoma.
Wieder SY; Serasinghe MN; Sung JC; Choi DC; Birge MB; Yao JL; Bernstein E; Celebi JT; Chipuk JE
J Invest Dermatol; 2015 Oct; 135(10):2544-2547. PubMed ID: 26032958
[No Abstract] [Full Text] [Related]
44. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
[No Abstract] [Full Text] [Related]
45. Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma.
Sobrevilla-Moreno N; Rivera-Sánchez D; García-Ortega D; López-Macías D; Garcilazo-Reyes A; Álvarez-Avitia M
Oncology (Williston Park); 2021 Sep; 35(9):562-566. PubMed ID: 34529396
[No Abstract] [Full Text] [Related]
46. Different growth and metastatic phenotypes associated with a cell-intrinsic change of Met in metastatic melanoma.
Adachi E; Sakai K; Nishiuchi T; Imamura R; Sato H; Matsumoto K
Oncotarget; 2016 Oct; 7(43):70779-70793. PubMed ID: 27683122
[TBL] [Abstract][Full Text] [Related]
47. BRAFV600E mutation in oral melanocytic nevus and oral mucosal melanoma.
Resende TAC; de Andrade BAB; Bernardes VF; Coura BP; Delgado-Azãnero W; Mosqueda-Taylor A; de Almeida OP; Gomes CC; Gomez RS
Oral Oncol; 2021 Mar; 114():105053. PubMed ID: 33189579
[No Abstract] [Full Text] [Related]
48. Metastatic melanoma of the oral cavity showing prompt regression with the use of BRAF/MEK inhibitors.
Oya K; Ishizuki S; Yasunaga S; Fujisawa Y; Nomura T
J Dermatol; 2024 Mar; 51(3):e61-e62. PubMed ID: 37904611
[No Abstract] [Full Text] [Related]
49. Multiple Primary Acral Lentiginous Melanoma on the Feet Developing in Lesions of Nagashima-type Palmoplantar Keratoderma.
Adachi A; Komine M; Maekawa T; Murata S; Shiohama A; Kubo A; Ohtsuki M
Acta Derm Venereol; 2017 Jun; 97(6):756-758. PubMed ID: 28224164
[No Abstract] [Full Text] [Related]
50. The conquest of melanoma by immunotherapy.
Lejeune FJ
Melanoma Res; 2015 Oct; 25(5):373-5. PubMed ID: 26173006
[No Abstract] [Full Text] [Related]
51. Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
Houben R; Ortmann S; Drasche A; Troppmair J; Herold MJ; Becker JC
J Invest Dermatol; 2009 Feb; 129(2):406-14. PubMed ID: 18650848
[TBL] [Abstract][Full Text] [Related]
52. New Potential Agents for Malignant Melanoma Treatment-Most Recent Studies 2020-2022.
Kozyra P; Krasowska D; Pitucha M
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682764
[TBL] [Abstract][Full Text] [Related]
53. RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells.
Berger A; Quast SA; Plötz M; Kuhn NF; Trefzer U; Eberle J
J Invest Dermatol; 2014 Feb; 134(2):430-440. PubMed ID: 23955071
[TBL] [Abstract][Full Text] [Related]
54. Mutant BRAF: a novel mediator of microenvironmental escape in melanoma?
Smalley KS
J Invest Dermatol; 2013 May; 133(5):1135-7. PubMed ID: 23594535
[TBL] [Abstract][Full Text] [Related]
55. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
Hao H; Muniz-Medina VM; Mehta H; Thomas NE; Khazak V; Der CJ; Shields JM
Mol Cancer Ther; 2007 Aug; 6(8):2220-9. PubMed ID: 17699719
[TBL] [Abstract][Full Text] [Related]
56. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma.
Mihic-Probst D; Perren A; Schmid S; Saremaslani P; Komminoth P; Heitz PU
Anticancer Res; 2004; 24(4):2415-8. PubMed ID: 15330192
[TBL] [Abstract][Full Text] [Related]
57. [Melanoma and search for therapeutic targets].
de la Fouchardière A
Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
[No Abstract] [Full Text] [Related]
58. [New treatments for metastatic melanoma: a first hope].
Robert C; Mateus C
Rev Prat; 2011 Nov; 61(9 Suppl):S1-2. PubMed ID: 22338196
[No Abstract] [Full Text] [Related]
59. BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas.
Jin SA; Chun SM; Choi YD; Kweon SS; Jung ST; Shim HJ; Yun SJ
J Invest Dermatol; 2013 Feb; 133(2):579-82. PubMed ID: 23014346
[No Abstract] [Full Text] [Related]
60. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
Lang N; Weisser A; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
